Reports Q3 revenue $338.97M, consensus $332.72M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Third quarter revenue growth, margin expansion, and cash flow reflect the underlying strength of our core businesses. Blood Management Technologies and Plasma continue to drive our strong performance while we take targeted actions to reestablish momentum in Interventional Technologies and prepare for a US launch of PerQseal Elite. We are well positioned to finish the fiscal year strong and deliver our long-term growth and value creation objectives throughout our business.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- HAE Upcoming Earnings Report: What to Expect?
- Balancing Plasma Strength Against Vascular Closure Uncertainty: Maintaining a Neutral (Hold) View on Haemonetics
- Orchestra BioMed to receive up to $21M in proceeds from Vivasure acquisition
- Haemonetics price target raised to $93 from $90 at Barrington
- Haemonetics acquires Vivasure to expand structural heart portfolio